Human insulin Market Size, Share Report, Analysis, Trends, Growth 2032

Global Human insulin Market Insights

According to a report from Zion Market Research, the global Human insulin Market was valued at USD 21.88 Billion in 2023 and is projected to hit USD 48.51 Billion by 2032, with a compound annual growth rate (CAGR) of 8.3% during the forecast period 2024-2032. This report explores market strengths, weakness, opportunities, and threats. It also provides valuable insights into the market's growth drivers, challenges, and the future prospects that may emerge in the Human insulin Market industry over the next decade.

Request Free Sample

Human Insulin Market Overview

Human insulin is the term that describes synthetic insulin which is grown in a laboratory to mimic the insulin in humans. In a laboratory, it is created by growing insulin proteins within E-coli bacteria (Escherichia coli). It is mainly available in two forms, a short acting (regular) form and an intermediate acting (NPH) form. Human insulin was developed as an insulin that could be created in large amounts at a relatively low cost. It can be administered orally or through insulin infusion devices. Some conventional insulin infusion devices are syringes, insulin pumps, and injection pens. These devices are used to deliver insulin on time and regularly.

Diabetes is described as a group of metabolic diseases in which the person has high blood glucose level than normal, either because insulin production is inadequate, or because the body's cells do not respond properly to insulin. Diabetes is a lifelong condition that is characterized by a raised blood glucose level. Diabetes is characterized into two types of diabetes: Insulin dependent diabetes mellitus (type 1) and Non-insulin dependent diabetes mellitus (type 2). Signs of diabetes include an increased sense of thirst, frequent urination, fatigue, weight and muscle loss, delayed wound healing and blurred vision. Human insulin therapy is utilized for the treatment of both type1 and type 2 diabetes mellitus.

Human Insulin Market Growth Factors

The global human insulin market is likely to see noteworthy development in the years to come. This development in global human insulin market is attributed owing to the rising market demand for human insulin analogs, increasing risk of diabetes, favorable medical reimbursements, and technological enactments in the field of human insulin delivery devices. An insulin routine is often needed in the treatment of gestational diabetes and diabetes related with specific syndromes or conditions (such as chemical or drug-induced diabetes, pancreatic diseases, insulin-receptor disorders, endocrinopathies, and specific genetic syndromes). In all cases of insulin employment, the dosage of insulin must be balanced and individualized with exercise and medical nutrition therapy, thereby boosting the global human insulin market.

Request Free Sample

Human insulin Market: Report Scope

Segment Analysis Preview  

Based on products, the global human insulin market is segmented into two types: drugs and drug delivery devices. Drugs segment of human insulin market was contributing maximum market shares in 2015 followed by drug delivery devices. This segment is propelled by factors which include increasing in insulin dependent diabetic population, low cost, growing R&D for drug discovery, rising proportion of aging population in developed countries. In addition, increasing market accessibility of generic human insulin and rising government initiatives to support the development and commercialization of effective biosimilars are expected to fuel the growth of human insulin market over the forecast period 

Based on drug type, the global human insulin market is segmented into two types: Biosimilars and Human Insulin Biologics. In terms of revenue, biosimilars were the leading segment of human insulin market in 2015 followed by human Insulin biologics. Meanwhile, biosimilar will rise approximately at a steady CAGR of 7.34% during the forecast period.

Based on application, the global human insulin market is segmented into two types: type 1 diabetes and type 2 diabetes. Type 1 diabetes mellitus was the dominating segment in terms of revenue generated in 2015 followed by type 2 diabetes mellitus. Type 1 Diabetes Mellitus is an autoimmune disorder characterized by a lack of insulin formation in the body. About 100,000 new cases are diagnosed annually in North America. Human insulin serves as only medication for treating type 1 diabetes mellitus.

Regional Analysis Preview  

North America has been leading the worldwide human insulin market and is anticipated to continue on the dominant position in the years to come. The factors such as growing old age population, rising prevalence of diabetes, increasing healthcare awareness, improvement in reimbursement policies, and surge in clinical trials driving the growth of human insulin in North America.

Request Free Sample

Key Market Players & Competitive Landscape

Some of the major players of the global human insulin market include

• Eli Lilly
• GlaxoSmithCline
• Biocon
• Sanofi Aventis
• Julphar
• Novo Nordisk
• SemBioSys
• and Wockhardt among others.

Request Free Sample

The global Human insulin Market is segmented as follows:

By Products

• Drugs
  • Insulin Analogs and Biosimilars
  • Human Insulin Biologics
• Drug Delivery Devices
  • Pens
  • Pen Needles
  • Syringes

By Applications

• Insulin dependent diabetes mellitus (Type 1)
• Non-Insulin dependent diabetes mellitus (Type 2)

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa